Danielle Brill
Stock Analyst at Raymond James
(1.29)
# 3,034
Out of 4,873 analysts
75
Total ratings
34.38%
Success rate
-10.05%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $14.33 | +262.88% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $20.39 | +218.78% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $14.45 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $54.14 | +45.92% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $8.55 | +110.53% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $127.78 | +21.30% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $15.75 | +128.57% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $31.57 | +26.70% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $17.46 | +759.11% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $127.31 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $9.25 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $445.82 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $560.53 | +7.93% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.50 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $31.76 | +57.43% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $32.71 | +55.92% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $53.92 | -20.24% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.33 | +1,433.74% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $48.89 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.71 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $14.33
Upside: +262.88%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $20.39
Upside: +218.78%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.45
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.14
Upside: +45.92%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $8.55
Upside: +110.53%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $127.78
Upside: +21.30%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $15.75
Upside: +128.57%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $31.57
Upside: +26.70%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $17.46
Upside: +759.11%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $127.31
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $9.25
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $445.82
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $560.53
Upside: +7.93%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.50
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $31.76
Upside: +57.43%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $32.71
Upside: +55.92%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $53.92
Upside: -20.24%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.33
Upside: +1,433.74%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $48.89
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.71
Upside: -